Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264912 | 1.00 | TSHR (0.46) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL5015252 | 0.86 | TSHR (0.53) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL12306815 | 0.83 | TSHR (0.40) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL4813841 | 0.80 | MEN1 (0.36) | TSHR | |
| SCHEMBL4813823 | 0.80 | MEN1 (0.36) | TSHR | |
| SCHEMBL5312037 | 0.79 | TSHR (0.46) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL5312040 | 0.79 | TSHR (0.46) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL6631037 | 0.78 | TSHR (0.50) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL7526044 | 0.77 | TSHR (0.56) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL11341588 | 0.77 | TSHR (0.43) | TSHRTP53TDP1PPARDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558461-B1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL MYERS SQUIBB CO (US) | 2015-12-02 | — | — | EP | disclosed |
| US-8993158-B2 | Nonaqueous electrolyte solution containing silyl ester group-containing phosphonic acid derivative, and lithium secondary battery | MITSUI CHEMICALS, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993158-B2 | Nonaqueous electrolyte solution containing silyl ester group-containing phosphonic acid derivative, and lithium secondary battery | MITSUI CHEMICALS, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130071732-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SILYL ESTER GROUP-CONTAINING PHOSPHONIC ACID DERIVATIVE, AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130071732-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SILYL ESTER GROUP-CONTAINING PHOSPHONIC ACID DERIVATIVE, AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2008120854-A1 | FLAMEPROOF COPOLYMER AND FLAME RETARDANT THERMOPLASTIC RESIN COMPOSITION USING THEREOF | CHEIL INDUSTRIES INC. (KR) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242795-A1 | Flameproof Copolymer and Flame Retardant Thermoplastic Resin Composition Including the Same | CHEIL INDUSTRIES INC. (KR) | 2008-10-02 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-4206156-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1980-06-03 | — | — | US | disclosed |
| US-4182758-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071732-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SILYL ESTER GROUP-CONTAINING PHOSPHONIC ACID DERIVATIVE, AND LITHIUM SECONDARY BATTERY | PHOSPHO1, PSPH, SGK2 | TSHR 4500/4885TP53 1848/4885TDP1 3359/4885 |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | TSHR 1541/4885TP53 2980/4885TDP1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.